SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Nvidia Options Price in $280 Billion Earnings Swing 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Trump Buys SpaceX Shares After Record IPO 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Tesla Raises Cybertruck Prices by $5,000 in US 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Add as a preferred source on Google
WALTHAM, Mass., May 01, 2018 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Bank of America Merrill Lynch 2018 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 15, 2018. Tim Pearson, EVP and CFO of TESARO, will participate in an analyst-led moderated Q&A at 4:20 PM PT and in meetings with investors.
- The Leerink Boston Biopharma Bus Tour on Thursday, May 17, 2018. Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications and Investor Relations
+1.781.325.1116 or [email protected]
Kate Rausch
Associate Director, Investor Relations
1.781-257-2505 or [email protected]
